<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>NK cell deficiency syndromes: Clinical manifestations and diagnosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">NK cell deficiency syndromes: Clinical manifestations and diagnosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">NK cell deficiency syndromes: Clinical manifestations and diagnosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jordan S Orange, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer M Puck, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anna M Feldweg, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 30, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Natural killer (NK) cells are innate lymphocytes that are critical in defense against virally infected cells and in tumor surveillance [<a href="#rid1">1-4</a>]. These cells are considered part of the innate immune system because they do not require previous exposure to foreign, pathogenic, or dangerous antigens to act. NK cells are the original members of a larger family of "innate lymphoid cells" (ILCs), each having particular roles and functions [<a href="#rid5">5,6</a>]. NK cells are the longest studied and best established of all the ILCs.</p><p>The importance of NK cells in human health and disease is illustrated by a small number of human diseases in which NK cells are absent or defective. These conditions are primarily characterized by severe, recurrent, or atypical infections with herpes viruses.</p><p>The biology of NK cells, the clinical manifestations of isolated NK cell deficiency syndromes, the evaluation of patients suspected to have these disorders, and the differential diagnosis will be discussed here [<a href="#rid7">7</a>]. The management of patients with NK cell deficiency syndromes is presented separately. (See  <a class="medical medical_review" href="/z/d/html/3922.html" rel="external">"NK cell deficiency syndromes: Treatment"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">BIOLOGY OF NK CELLS</span><span class="headingEndMark"> — </span>NK cells are lymphocytes that originate in the bone marrow and comprise 2 to 18 percent of the peripheral blood lymphocyte pool [<a href="#rid8">8-11</a>]. Although low in number, they are the main lymphocytes of the innate immune system in the peripheral blood. NK cells account for a minority of lymphocytes within organs in most cases, although there are important exceptions. In the duodenal epithelia and in the uterine decidua during pregnancy, NK cells account for up to 45 and 70 percent of lymphocytes, respectively [<a href="#rid12">12,13</a>].</p><p class="headingAnchor" id="H3"><span class="h2">Phenotypic characteristics</span><span class="headingEndMark"> — </span>NK cells do not display the same cell surface markers as other populations of lymphocytes. Specifically, they do not have CD3, CD4, or CD19. Instead, the majority of mature NK cells (although not all) display the following surface molecules [<a href="#rid14">14,15</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>CD16</strong> – The Fc-gamma-RIIIa receptor for immunoglobulin (Ig)G</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CD56</strong> – A neural cell adhesion molecule</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CD158</strong> – A member of the killer cell immunoglobulin-like receptor (KIR) family, many of which serve as receptors for class I major histocompatibility complex (MHC) molecules.</p><p></p><p>In standard lymphocyte flow cytometry panels, NK cells are typically characterized as CD3-, CD16/56+. Some laboratories will report CD56+ and CD16+ NK cells separately, although it is still very common for the "either/or" approach to CD16/CD56 to be used. Approximately one-half of NK cells express CD8, although these are CD8 alpha/alpha homodimers, unlike the CD8 alpha/beta heterodimers expressed on cytotoxic T cells.</p><p>NK cells can be distinguished from other lymphocytes on electron microscopy by the presence of large cytoplasmic granules containing the enzymes and other molecules used in cytotoxicity  (<a class="graphic graphic_picture graphicRef76027" href="/z/d/graphic/76027.html" rel="external">picture 1</a>).</p><p class="headingAnchor" id="H3442005322"><span class="h2">Subsets</span><span class="headingEndMark"> — </span>The majority of NK cells in the peripheral blood express intermediate levels of CD56 and are referred to as "CD56<sup>dim</sup>." A minor population (approximately 6 percent, which trends higher in very young children) has very high expression of CD56 and is referred to as "CD56<sup>bright</sup>" [<a href="#rid9">9,11</a>]. However, there is a great diversity of NK cells present in the human body and a number of additional NK cell subsets corresponding specific stages of NK cell development or tissue distribution [<a href="#rid11">11,16</a>]. The two major peripheral blood subsets as reflected by CD56 expression have important functional and developmental differences:</p><p class="bulletIndent1"><span class="glyph">●</span>CD56<sup>dim</sup> NK cells are effectors of NK cell cytotoxicity and antibody-dependent cellular cytotoxicity (ADCC). (See <a class="local">'Mechanisms of killing'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CD56<sup>bright</sup> NK cells are effective at the production of cytokines but do not express the cytolytic machinery and mediate cytotoxicity only weakly. CD56<sup>bright</sup> NK cells are considered to be developmentally immature and have been shown to be a precursor to mature CD56<sup>dim</sup> NK cells. (See <a class="local">'Immunostimulation'</a> below.)</p><p></p><p class="headingAnchor" id="H4"><span class="h2">Functions</span><span class="headingEndMark"> — </span>An important function of NK cells in the innate immune system is cellular killing or cytotoxicity. NK cells constantly survey surrounding cells for abnormalities and kill those cells that fail to display various signatures of health, particularly virally infected and malignant cells. Multiple families of inhibitory receptors on the surface of NK cells, including the KIRs, act to restrain the destructive potential of these cells, mostly by recognizing and binding class I MHC on healthy cells. Additional NK cell functions include cytokine and chemokine production and costimulation of other immune cells [<a href="#rid17">17</a>].</p><p class="headingAnchor" id="H3379260668"><span class="h3">Mechanisms of killing</span><span class="headingEndMark"> — </span>The two primary killing mechanisms effected by NK cells are NK cell cytotoxicity and ADCC. Both mechanisms involve the release of lytic granule contents, which include the pore-forming molecule perforin, as well as cell death-inducing enzymes, such as granzyme serine esterases. NK cell cytotoxicity is the most rapid form of killing and represents an important defensive component of the innate immune system. ADCC involves the NK cell recognizing an immunoglobulin-bound target and, thus, interfaces with the adaptive immune system.</p><p>A third distinct type of killing is mediated by interactions between death receptors, such as Fas on a target cell and the cognate ligand expressed on an NK cell (ie, FasL in this example). The ligation of Fas by FasL induces apoptosis in the target cell [<a href="#rid18">18</a>]. The kinetics of this type of NK cell killing are slower than that mediated by perforin.</p><p class="headingAnchor" id="H6580232"><span class="h4">NK cell cytotoxicity</span><span class="headingEndMark"> — </span>NK cell cytotoxicity is a rapid process. During an acute viral infection, increased NK cell cytotoxicity is evident within three days [<a href="#rid14">14,19</a>]. By comparison, cytotoxic T cells are not capable of cytotoxicity prior to activation by viral exposure, and, once activated, their numbers and function begin to peak approximately one week later (following clonal expansion of those T cells having a T cell receptor specific for a viral peptide).</p><p>NK cells are considered part of the innate immune response because they act through receptors that are encoded in the germline DNA and do not undergo genetic recombination to attain specificity. This distinguishes them from lymphocytes of the adaptive immune system (ie, T, B, and natural killer T [NKT] cells), which recombine DNA following exposure to antigen and generate antigen-specific T cell receptors and immunoglobulins, respectively [<a href="#rid20">20</a>]. In addition, NK cells can mediate the destruction of target cells based entirely upon interactions between ligands expressed by the target cell and cognate receptors present on the NK cell. This activity does not require interaction with the adaptive immune system and is also called "natural" or "spontaneous" cytotoxicity.</p><p>NK cells constantly survey surrounding cells for abnormalities and rely upon the detection of various signatures of health to inhibit their potentially lethal functions. Restraining the activity of these cells are multiple families of cell surface inhibitory receptors, of which the KIR family is the best characterized. KIRs bind to the class I MHC molecules found on the surface of most nucleated cells, which identify the cell as "healthy self." NK cell killing is inhibited if class I MHC molecules are present in normal density. However, if class I MHC is deficient or missing, activation receptor signaling overcomes inhibitory receptor signaling, and NK cell functions are triggered. Thus, NK cells detect and can be triggered to destroy cells that are "missing self" [<a href="#rid21">21</a>].</p><p>Tumor cells and cells that are infected with certain viruses downregulate surface class I MHC molecules and are therefore recognized by NK cells as nonself and targeted for destruction. However, a variety of viruses have evolved to exploit this mechanism and escape NK cell-mediated defenses [<a href="#rid22">22,23</a>]. For example, some viruses encode for the expression of class I MHC decoy molecules. Others cause selective downregulation of those class I MHC molecules that are most likely to engage cytotoxic T lymphocytes, while having minimal effect on the class I MHC molecules detected by inhibitory KIRs on NK cells, thus allowing evasion of the T cell response and inhibition of NK cell cytotoxicity.</p><p>KIRs signal through cytoplasmic immunoreceptor tyrosine-based inhibitory motifs (ITIMs). Upon receptor ligation, tyrosines in these ITIMs are phosphorylated, allowing the recruitment of Src-homology tyrosine phosphatase (SHP). Recruited SHPs dephosphorylate a number of cellular targets to prevent NK cell activation directed at the target cell. The most notable is Vav-1, which is a direct requirement in the signaling leading to NK cell activation and cytotoxicity [<a href="#rid24">24</a>].</p><p>In contrast to KIRs, which restrain the killing activity of NK cells, there are numerous other receptors on the surface of NK cells that are capable of recognizing target cell ligands and generating signals that promote NK cell cytotoxicity. They all require surpassing a signaling threshold set by the negative signals arising from appropriately ligated inhibitory receptors. Some activating receptors are potent in their function, while others require the cooperative efforts of multiple receptors to achieve an appropriate signaling threshold. A few of the receptors, such as 2B4 (CD244), NKG2D, and LFA-1 (CD11a/CD18), are involved in activation of NK cells as well as other cell types. Others are specific to NK cells, including the natural cytotoxicity receptor family [<a href="#rid25">25,26</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>NKp44 (CD336) and NKp46 (CD335), which bind viral hemagglutinin [<a href="#rid27">27</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>NKp30 (CD337), which binds human leukocyte antigen (HLA)-B-associated transcript 3 and H7-B6</p><p></p><p>These receptors transmit intracellular signals through the immunoreceptor tyrosine-based activation motifs, mobilizing intracellular calcium. Intracellular calcium then enables the fusion and secretion of NK cell lytic granules with the NK cell membrane where it touches the target cell. This contact leads to secretion of lytic granule contents onto the target cell to promote cytotoxicity. A single NK lytic granule is capable of mediating a fatal blow to a target cell, although, more typically, between two and five granules lead to the irreversible death of the target [<a href="#rid28">28</a>]. The cell death induced by an NK cell is a combination of apoptosis and necrosis [<a href="#rid29">29</a>].</p><p>The interface between the NK cell and target, as well as the molecular arrangements that occur at that site, are collectively referred to as the NK cell immunologic synapse [<a href="#rid30">30</a>]. The organization, maturation, and function of the NK cell immunologic synapse progresses in a stepwise manner and can be specifically affected by certain genetic diseases of the immune system, most notably the Wiskott-Aldrich syndrome and the congenital hemophagocytic syndromes. (See <a class="local">'Genetic disorders and other immunodeficiencies'</a> below.)</p><p class="headingAnchor" id="H6580441"><span class="h4">Antibody-dependent cellular cytotoxicity</span><span class="headingEndMark"> — </span>A well-characterized function of NK cells is antibody-dependent cellular cytotoxicity (ADCC), which is a variation of NK cell cytotoxicity that cooperates with the humoral immune system to facilitate elimination of targets recognized by specific IgG. CD16 (the Fc-gamma-RIIIa receptor) on the surface of the NK cell binds to the Fc portion of IgG. IgG, in turn, is attached to a cell or organism through its antigen-recognition sites in the Fab portion. This can be through the NK cell recognizing IgG opsonized targets or through multiple NK cell CD16 molecules being pre-loaded with IgG specific for a target. Unopposed, these interactions activate the NK cell, leading to ADCC of the target cell. However, as is the case with other types of cytotoxicity receptors, activation is countered by the presence of inhibitory receptors that keep the cytotoxic functions of the cell in check. ADCC is important to the mechanism of certain biologic therapies, and some cell-targeting monoclonal antibodies utilize NK cell ADCC to eliminate the targeted cell. One example is <a class="drug drug_general" data-topicid="115768" href="/z/d/drug information/115768.html" rel="external">benralizumab</a>, which targets eosinophils via the interleukin (IL-)5 receptor and uses NK cell ADCC to destroy them [<a href="#rid31">31,32</a>].</p><p class="headingAnchor" id="H5"><span class="h3">Immunostimulation</span><span class="headingEndMark"> — </span>NK cells, particularly those that are CD56<sup>bright</sup>, serve important roles in immune responses and host defense through their ability to produce and secrete various cytokines and chemokines. NK cells are best known for their ability to secrete interferon (IFN)-gamma after activation. This enables them to participate in antiviral responses through the direct and immunostimulatory properties of this cytokine. IFN-gamma produced by NK cells is also useful in activating macrophages and facilitating their respiratory burst.</p><p>NK cells also produce tumor necrosis factor and, under certain circumstances, IL-5 and IL-13 (among others). These last two cytokines may facilitate humoral immunity, although they also suggest a possible pathogenic role for NK cells in asthma and atopic conditions, as IL-5 and IL-13 are main drivers of eosinophil development and differentiation.</p><p class="headingAnchor" id="H4200563284"><span class="h2">Relationship to NKT cells</span><span class="headingEndMark"> — </span>NK cells are distinct from NKT cells. NKT cells are a subset of T lymphocytes. They are CD3+, CD16/CD56+ and rearrange their T cell receptor genes, as do conventional T cells. There is a clinical entity of NKT cell deficiency [<a href="#rid33">33</a>], and NKT cells are also deficient in a variety of other conditions [<a href="#rid34">34</a>]. NKT cells are not discussed further in this review.</p><p class="headingAnchor" id="H1452436201"><span class="h2">Relationship to innate lymphoid cells</span><span class="headingEndMark"> — </span>NK cells are an innate lymphoid cell (ILC) and are most closely related to ILC1s, although NK cells have distinguishing characteristics of their own. In general, the ILCs participate specifically in particular aspects of immune regulation and targeted host defense. (See  <a class="medical medical_review" href="/z/d/html/13572.html" rel="external">"An overview of the innate immune system", section on 'Innate lymphoid cells'</a>.)</p><p class="headingAnchor" id="H9"><span class="h1">CLINICAL FEATURES OF NK DISORDERS</span><span class="headingEndMark"> — </span>As a group, true NK cell deficiency disorders are rare, with fewer than 100 cases reported in the literature. However, as with all primary immunodeficiencies, now called inborn errors of immunity (IEIs), milder cases are being identified as the ability to make definitive molecular diagnoses improves.</p><p class="headingAnchor" id="H839665507"><span class="h2">Viral infections</span><span class="headingEndMark"> — </span>The primary presenting feature in the majority of cases described is severe, recurrent, or atypical infections with herpes viruses and cutaneous wart-causing papilloma viruses.</p><p>The most commonly implicated herpes viruses in patients with these disorders include:</p><p class="bulletIndent1"><span class="glyph">●</span>Cytomegalovirus (CMV)</p><p class="bulletIndent1"><span class="glyph">●</span>Varicella-zoster virus (VZV)</p><p class="bulletIndent1"><span class="glyph">●</span>Herpes simplex viruses (HSV) I and II</p><p class="bulletIndent1"><span class="glyph">●</span>Epstein-Barr virus (EBV)</p><p></p><p>Patients may develop fulminant VZV, CMV, or EBV infection in childhood or adolescence, leading to prolonged hospitalization, critical illness, or even death. Other clinical scenarios include recurrent VZV presenting as repeated primary infections or frequent herpes zoster. For patients with HSV, infections may affect multiple dermatomes, impact internal organs, or require pharmacologic suppression to prevent frequent eruptions. Cutaneous warts caused by papilloma viruses are less commonly seen compared with herpes viruses.</p><p class="headingAnchor" id="H4011471833"><span class="h2">Risk of malignancy</span><span class="headingEndMark"> — </span>Many IEIs increase the risk of malignancies, and NK cell deficiencies may also have this effect. Patients with GATA2 deficiency develop human papillomavirus-associated cancers [<a href="#rid35">35</a>], but the data in patients with other causes of NK deficiencies are scant, although it held to represent a risk [<a href="#rid36">36</a>].</p><p class="headingAnchor" id="H871033052"><span class="h2">Natural history</span><span class="headingEndMark"> — </span>Most of the individuals described have died in childhood or adolescence, unless they underwent hematopoietic cell transplantation, demonstrating the importance of NK cells in defense against specific viral infections. However, some have survived without transplantation, suggesting that there may be a period in the patient's life when NK cell function is most critical. In addition, even within families sharing the same variants, severity can vary dramatically [<a href="#rid37">37</a>]. (See  <a class="medical medical_review" href="/z/d/html/3922.html" rel="external">"NK cell deficiency syndromes: Treatment"</a>.)</p><p class="headingAnchor" id="H689879464"><span class="h1">CLASSIFICATION</span><span class="headingEndMark"> — </span>Isolated NK cell deficiencies are disorders in which the NK cell number or function is either the only or the predominant defect resulting in the clinical immunodeficiency. This distinction is important because the list of identified inborn errors of immunity (IEIs) is expanding rapidly, and some of these disorders include impaired NK cell number or function. In these other disorders, a deficit of NK cells does not account for the patient's clinical presentation or the deficit seems secondary to other immune defects that explain the clinical picture more completely. In a 2022 listing by the International Union of Immunological Societies expert committee, over 75 of the 400+ IEIs identified impacted NK cells [<a href="#rid38">38</a>].</p><p>NK cell deficiency syndromes can be divided into two types  (<a class="graphic graphic_table graphicRef50812" href="/z/d/graphic/50812.html" rel="external">table 1</a>) [<a href="#rid39">39</a>]:</p><p class="headingAnchor" id="H3155707212"><span class="h2">Classical NK cell deficiency</span><span class="headingEndMark"> — </span>Patients with classical NK cell deficiency (cNKD) usually present with severe, recurrent, or atypical herpes infections and papilloma viruses  (<a class="graphic graphic_table graphicRef50812" href="/z/d/graphic/50812.html" rel="external">table 1</a>).</p><p>cNKD results from interruption of normal NK cell development or survival. cNKD is characterized by absent or profoundly decreased (defined as ≤1 percent of peripheral lymphocytes) CD3-CD56+ NK cell numbers or a demonstrable developmental abnormality of NK cells [<a href="#rid10">10</a>]. Developmental abnormalities are usually detected as an excess of CD56<sup>bright</sup> cells, although there can be aberrations in the expression of other markers relevant to development, such as CD117, CD94, CD16, and the killer cell Ig-like receptors. Patients with low numbers of NK cells may be classified as having cNKD if function is also absent, particularly if the few cells present are all CD56<sup>bright</sup> (the type of NK cell that is not involved in cytotoxicity).</p><p class="headingAnchor" id="H4001283878"><span class="h2">Functional NK cell deficiency</span><span class="headingEndMark"> — </span>Functional NK cell deficiency (fNKD) represents a more diverse diagnosis in which NK cells are present (ie, &gt;1 percent of peripheral lymphocytes) but are persistently deficient in at least one of their functional activities. Patients with fNKD present with recurrent or atypical herpes infections and papilloma viruses, similar to cNKD, although usually less severe  (<a class="graphic graphic_table graphicRef50812" href="/z/d/graphic/50812.html" rel="external">table 1</a>). Because the overall number or percentage of NK cells is not abnormal, fNKD is more challenging to diagnose.</p><p class="headingAnchor" id="H2741353700"><span class="h1">PATHOGENESIS</span></p><p class="headingAnchor" id="H967085748"><span class="h2">Classical NK cell deficiency</span><span class="headingEndMark"> — </span>A small number of variants have been identified in patients with classical NK cell deficiency (cNKD). It is not known what percentage of cNKD cases is attributable to each variant.</p><p class="headingAnchor" id="H454667"><span class="h3">Autosomal dominant GATA2 deficiency</span><span class="headingEndMark"> — </span>An autosomal dominant variant in the gene <em>GATA2</em>, which encodes a widely expressed transcription factor required for maintenance of the stem cell pool, has been identified in some patients with cNKD type 1 (cNKD1). GATA2 deficiency is the only autosomal dominant variant known to cause cNKD.</p><p>The most cited case is that of an adolescent female who presented with disseminated and life-threatening varicella-zoster virus (VZV) infection [<a href="#rid40">40</a>]. She had a prior history of recurrent otitis media and intermittent leukopenia but was otherwise well. In late adolescence, she had life-threatening systemic cytomegalovirus (CMV) infection followed by disseminated herpes simplex virus infection. The patient had evidence of normal specific antibody production and lymphocyte responsiveness, as she had high titer IgG against VZV in her serum, and her peripheral blood lymphocytes produced interferon (IFN)-gamma after stimulation and demonstrated proliferation in the presence of VZV. She completely lacked CD56+ or CD16+ lymphocytes and NK cell cytotoxicity, even when her lymphocytes were stimulated in vitro with type I IFN or interleukin (IL-)2. She died during the course of hematopoietic cell transplantation and was posthumously found to have GATA2 haploinsufficiency [<a href="#rid41">41</a>].</p><p>A cohort of 18 patients was described a decade later with what appeared to be cNKD in the context of low numbers of monocytes, especially B cells [<a href="#rid42">42</a>]. Many of these patients had essentially no CD56+ NK cells and very low numbers of monocytes (which also express CD56, albeit at low levels). Some of these cases were familial. Severe human papillomavirus (HPV) infections, mycobacterial infections, and fungal infections were reported in 78, 78, and 28 percent of cases, respectively. Variants in the <em>GATA2</em> gene were subsequently identified [<a href="#rid41">41,43,44</a>]. Some cases do have larger numbers of NK cells present, but they share the unusual characteristic of being deficient in the CD56<sup>bright</sup> NK cell subset [<a href="#rid41">41</a>].</p><p>However, GATA2 deficiency is a complex disorder that can present in different ways and affect multiple organs, as well as B cells and dendritic cells. All presentations of GATA2 deficiency are grouped together under the classification OMIM#614172. In some patients, GATA2 deficiency is associated with primary lymphedema with myelodysplasia, myelodysplastic syndrome, and acute myeloid leukemia, and these syndromes are not classified as cNKD [<a href="#rid45">45-48</a>]. Patients with these other presentations may have low or normal NK cell numbers [<a href="#rid10">10</a>]. The mechanism linking the presumably pervasive GATA2 transcription factor to the various phenotypes is unclear [<a href="#rid36">36</a>]. In a report of 57 patients with GATA2 variants, 82 percent had NK cell lymphopenia, and 70 percent had severe viral infections at early ages [<a href="#rid35">35</a>].</p><p>In summary, cNKD is one of the ways in which GATA2 deficiency can present clinically and immunologically. Other manifestations of GATA2 deficiency are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3958.html" rel="external">"Mendelian susceptibility to mycobacterial diseases: Specific defects", section on 'GATA2 deficiency (MonoMAC syndrome)'</a> and  <a class="medical medical_review" href="/z/d/html/93183.html" rel="external">"Familial disorders of acute leukemia and myelodysplastic syndromes", section on 'Familial MDS/AML with mutated GATA2'</a>.)</p><p class="headingAnchor" id="H454673"><span class="h3">MCM4 deficiency</span><span class="headingEndMark"> — </span>Variants in the minichromosome maintenance complex component 4 (MCM4), a DNA helicase that is involved in the unwinding and polymerization of chromosomal DNA, were identified in one large consanguineous family of Irish nomadic descent. The MCM helicase consists of a core set of MCM proteins (MCM2-7) and is required for DNA duplication to occur at replication forks, although how variants in this complex lead to the observed clinical abnormalities is not known [<a href="#rid49">49</a>]. Patients with MCM4 deficiency had short stature, developmental delay, and adrenal insufficiency. One affected family member had Epstein-Barr virus (EBV) lymphoproliferation, and two others had recurrent viral infections [<a href="#rid50">50</a>]. Linkage analysis performed using multiple family members defined 8p11.23-8q11.21 as a susceptibility locus. Subsequently, the genetic variant in these individuals was defined, and there are a total of three consanguineous cohorts [<a href="#rid49">49,51,52</a>]. These individuals lack NK cells but have a small number of CD56<sup>bright</sup> cells. They also have a profound somatic phenotype of adrenal insufficiency and growth retardation [<a href="#rid49">49,51</a>]. This disorder is listed in the Online Mendelian Inheritance in Man database (OMIM#609981) and has been termed "cNKD type 2" (cNKD2).</p><p class="headingAnchor" id="H878435365"><span class="h3">RTEL1 deficiency</span><span class="headingEndMark"> — </span>A previously healthy 23-month-old girl who presented with severe disseminated VZV infection that resulted in her death was found to have a deficiency of regulator of telomere elongation helicase 1 (RTEL1) [<a href="#rid53">53,54</a>]. She had normal proportions of B and T cells, as well as a proliferative response to T and B cell mitogens and normal immunoglobulin levels. However, NK cytotoxicity was markedly decreased and could not be restored with preincubation with IL-2. RTEL1 deficiency is also a reported cause of Hoyeraal-Hreidarsson syndrome, which presents with dyskeratosis congenita, bone marrow failure, and immunodeficiency [<a href="#rid55">55</a>]. However, the patients with cNKD did not have these clinical disorders. (See  <a class="medical medical_review" href="/z/d/html/100663.html" rel="external">"Dyskeratosis congenita and other telomere biology disorders", section on 'Hoyeraal-Hreidarsson syndrome'</a>.)</p><p class="headingAnchor" id="H261886415"><span class="h3">IRF8 deficiency</span><span class="headingEndMark"> — </span>Biallelic (ie, affecting both alleles of the gene but not necessarily with the identical variants) variants in the gene for interferon regulatory factor 8 (<em>IRF8</em>) were identified in a family with severe EBV infections, absent NK cell function, and increased CD56<sup>bright</sup> NK cells [<a href="#rid37">37,56</a>]. IRFs are transcription factors that help shape the inflammatory response, particularly to viral infections. The clinical disorder was originally noted in three siblings who developed severe and prolonged EBV infection requiring intensive hospitalization [<a href="#rid56">56</a>]. One male died during the acute illness, one female survived but died years later from pulmonary complications, and a third male survived into his fifth decade but with continued viral respiratory infections. This individual had a paucity of CD56<sup>dim</sup> NK cells, with a relative expanded presence of CD56<sup>bright</sup> NK cells [<a href="#rid37">37</a>]. A fourth sibling was unaffected and had a normal clinical course after EBV infection. Through whole exome sequencing (WES), compound heterozygous variants in IRF8 were identified with appropriate segregation through the family, with the unaffected sibling having only one aberrant allele. Children of the affected surviving male with single aberrant IRF8 alleles also had normal NK cell numbers and function. Through biologic investigations, it was determined that IRF8 is required for normal NK cell maturation and that it activates transcriptional programs central to NK cell development. Individuals with select single damaging variants in IRF8 can have a mild dendritic cell subset abnormality, predisposing them to mycobacterial infections [<a href="#rid57">57</a>]. Through that work, two additional families having biallelic IRF8 variants were identified (one had mycobacterial infection and the other recurrent respiratory infections), and both had decreased total NK cells along with elevated CD56<sup>bright</sup> NK cells [<a href="#rid37">37</a>]. In contrast, both of the IRF8 variants in the original family were in a specific domain of the protein (the IRF domain) and did not have obvious dendritic cell abnormalities, suggesting that the lack of dendritic cell abnormalities might be a feature of having IRF domain variants.</p><p class="headingAnchor" id="H1192188903"><span class="h3">GINS1 deficiency</span><span class="headingEndMark"> — </span>One of the original families clinically and phenotypically reported as having NK cell deficiency was defined as having compound heterozygous variants in the Go-Ichi-Ni-San-1 (<em>GINS1</em>) gene [<a href="#rid58">58</a>]. GINS1 is part of what is known as the CDC45-MCM10-GINS complex, which is required for the function of the MCM helicase. The original clinical description of individuals affected by GINS1 deficiency was a nonconsanguineous French family, in which two children were affected and the older died from severe CMV infection [<a href="#rid59">59</a>]. They had severe growth retardation and facial abnormalities, suggesting a syndromic immunodeficiency. They also had neutropenia and abnormalities in lymphocyte survival, as well as decreased numbers of natural killer T cells, mucosal-associated invariant T cells, and innate lymphoid cells (ILC2s and ILC3s). The surviving sister was previously shown to have impaired lymphoid cell survival in response to IL-2 and IL-15 [<a href="#rid60">60</a>].</p><p>Ongoing studies and evaluation through WES identified compound heterozygous GINS1 variants in the proband and also identified three unrelated families having the same variant, also in conjunction with NK cell deficiency. All had viral susceptibility, and most had growth retardation and facial dysmorphism. All patients had very low NK cells, with a selective depletion of the CD56<sup>dim</sup> subset. While presumably mechanistically linked to MCM4 deficiency, biologic studies demonstrated that the presence of biallelic GINS1 variants resulted in replication instability and cell cycle abnormalities. Patients with the variants had about 1/10 the GINS1 function of normal individuals. However, the specific role of GINS1 in NK cells remains unclear.</p><p class="headingAnchor" id="H2583552525"><span class="h3">MCM10 deficiency</span><span class="headingEndMark"> — </span>Compound heterozygous variants in minichromosomal maintenance complex member 10 (MCM10) have been described in a single patient, a 16-month-old with progressive CMV and essentially no NK cells in peripheral blood [<a href="#rid61">61</a>]. One variant was a truncation preventing nuclear translocation, and the second was a missense that reduced protein function. Neither parent had abnormalities, and the patient's other immunological parameters were either normal or near normal. Interestingly, the few NK cells found in the peripheral blood were mostly of the CD56<sup>bright</sup> immature variety, mirroring findings in MCM4 and GINS1 deficiencies. This child with MCM10 deficiency did not have adrenal insufficiency or intrauterine growth delay, potentially distinguishing MCM10 deficiency from MCM4 and GINS1 deficiencies. While a variety of clinical interventions were attempted in this case, including hematopoietic stem cell transplantation, the child did not survive. It remains unclear why abnormalities in the MCM complex result in a specific NK cell abnormality, although a variety of studies performed related to this case demonstrated that intact MCM10 function was required for NK cell terminal maturation and resulting function [<a href="#rid61">61</a>]. Separately, the patient's variants were shown to affect telomere maintenance, which could represent a common mechanism among some of these MCM-related NKDs [<a href="#rid62">62</a>].</p><p class="headingAnchor" id="H3908396582"><span class="h3">GINS4 deficiency</span><span class="headingEndMark"> — </span>Siblings with compound heterozygous variants in the MCM complex member GINS4 were identified after the proband was evaluated for severe CMV, VZV, and recurrent HSV. The proband also had recurrent infections and a history of intrauterine growth restriction. The proband's sister had recurrent localized HSV. Both siblings had low NK cell counts and some neutropenia, but normal T and B cell counts and subsets. The GINS4 variants found in these patients both decreased expression of the protein and led to abnormal protein function. Normal function was experimentally found to be required for NK cell cycle progression and NK cell differentiation. Like other NKD patients with MCM complex abnormalities, there was a relative overrepresentation of CD56<sup>bright</sup> immature NK cells among NK cells found in peripheral blood.</p><p class="headingAnchor" id="H3239728966"><span class="h3">Unknown etiology</span><span class="headingEndMark"> — </span>In a referral program maintained by the author, and in others shared with the author, most cases fitting the diagnosis of cNKD do not have one of the identified variants listed above. When possible, specimens from patients are retested as new variants are described, and unbiased research-level sequencing approaches have been employed. There are also several case reports in the literature in which a specific defect has not been identified [<a href="#rid63">63-66</a>].</p><p class="headingAnchor" id="H454019"><span class="h2">Functional NK cell deficiency</span></p><p class="headingAnchor" id="H454635"><span class="h3">FCGR3A defects</span><span class="headingEndMark"> — </span>In a few patients, a detrimental functional variant in the gene coding for CD16 (Fc-gamma-RIIIa), <em>FCGR3A</em>, has been identified. This is the only known single gene variation to give rise to an isolated functional NK cell deficiency (fNKD). This is informative because it connects a specific cell activity to the expression of a single gene that is relevant mainly to NK cells. CD16 is expressed on the vast majority of NK cells, as well as some phagocytes. The function of CD16 on the surface of phagocytes is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/3975.html" rel="external">"The adaptive humoral immune response", section on 'Opsonization'</a>.)</p><p>Several individuals have been reported who are homozygous for a T to A substitution at position 230 in <em>FCGR3A</em>, resulting in the substitution of a histidine at position 66 in the CD16 molecule (referred to as the "L66H alteration") [<a href="#rid67">67-69</a>]. All had recurrent, progressive, or severe herpesvirus infections.</p><p>The L66H alteration disrupts the interaction between the distal extracellular domain of CD16 and other NK cell receptors (CD2 in particular). In three patients from different families who were homozygous for the L66H alteration, NK cell cytotoxicity was impaired but antibody-dependent cellular cytotoxicity was normal, suggesting that CD16 plays a role in IgG-independent NK cell function [<a href="#rid67">67,68,70</a>]. The frequency of the CD16 L66H allele appears to be rare in modern genomic databases [<a href="#rid67">67</a>], although it may be quite high in certain populations (eg, White Scandinavian patients) [<a href="#rid70">70</a>].</p><p class="headingAnchor" id="H143014799"><span class="h3">Unknown etiology</span><span class="headingEndMark"> — </span>Other individuals appear to have fNKD without an identifiable genetic etiology, as no NK cell-specific defect has been found. These patients also suffered from recurrent viral infections and severe or invasive herpesvirus infections [<a href="#rid71">71-73</a>]. All had otherwise normal immunologic phenotypes and normal demonstrable T cell and B cell function. None had other immunologic disorders that could potentially interfere with NK cell development, survival, or activity. In all cases, the NK cell defect was persistent in serial assessments, and the author is aware of others that fit this description via the author’s referral program.</p><p class="headingAnchor" id="H19284438"><span class="h1">REFERRAL</span><span class="headingEndMark"> — </span>Patients with clear evidence of severe, recurrent, or atypical herpes infections should be referred to an expert in either allergy/immunology or infectious diseases and with experience in evaluating the immune system. The initial evaluation includes flow cytometric tests to quantitate NK cells and other lymphocyte subsets, which are widely available, but advanced testing often requires laboratories specializing in immunodeficiency. Referral to a center of expertise should occur when the patient's presentation has been determined to be sufficiently abnormal to an experienced clinician in allergy/immunology or infectious diseases. Several centers have expertise in NK cell deficiencies [<a href="#rid74">74</a>].</p><p class="headingAnchor" id="H10456093"><span class="h1">EVALUATION AND DIAGNOSIS</span></p><p class="headingAnchor" id="H272398349"><span class="h2">When to suspect an NK cell disorder</span><span class="headingEndMark"> — </span>Evaluation for an NK cell deficiency syndrome should be considered in patients with severe, recurrent, or atypical herpes infections  (<a class="graphic graphic_table graphicRef50812" href="/z/d/graphic/50812.html" rel="external">table 1</a>). In most cases, the possibility of an NK cell defect is raised only after a severe, debilitating, chronic, or potentially irreversible infectious disease. (See <a class="local">'Viral infections'</a> above.)</p><p class="headingAnchor" id="H3945632749"><span class="h2">Assessing current and past infections</span><span class="headingEndMark"> — </span>Pathogens of the herpesvirus family that have caused significant current or past infections are most relevant to consider. Current infections are usually identified by culture, polymerase chain reaction (PCR), or antigenic or serologic tests. Methods of evaluating past infections include postexposure titers, in vitro lymphocyte proliferation or cytokine production in response to pathogen or pathogen-derived antigen exposure, and cytotoxic T lymphocyte-mediated cytotoxicity against allogeneic cells infected with the suspected organism. These tests may be available at some advanced centers. Assessing the past exposure history of a potentially NK cell-deficient patient is also helpful in planning future management. (See  <a class="medical medical_review" href="/z/d/html/3922.html" rel="external">"NK cell deficiency syndromes: Treatment"</a>.)</p><p class="headingAnchor" id="H4119081492"><span class="h2">Initial testing</span><span class="headingEndMark"> — </span>A complete blood count (CBC) with differential should be performed initially, although this does not provide information about lymphocyte subsets. CBC is usually normal in patients with classical NK cell deficiency (cNKD) or functional NK cell deficiency (fNKD), although some may have low lymphocytes.</p><p>The number of NK (CD3-, CD56/16+) cells, as well as T and B cells can be determined with a standard flow cytometry panel performed on peripheral blood.</p><p>Other testing that is usually performed before more advanced NK cell studies include lymphocyte responses to mitogens and antigens, immunoglobulin levels (IgG, IgA, IgM, and IgE), and response to protein and polysaccharide vaccines. Abnormalities in any of these studies should prompt further advanced testing. (See  <a class="medical medical_review" href="/z/d/html/3903.html" rel="external">"Laboratory evaluation of the immune system"</a>.)</p><p class="headingAnchor" id="H845759699"><span class="h2">Cytotoxicity testing</span><span class="headingEndMark"> — </span>Cytotoxicity testing of peripheral blood lymphocytes is used to assess NK function. A chromium release assay (using <sup>51</sup>Cr) is the classical and standard method, although a variety of flow cytometry-based target cell death assays can accomplish the same objective. This test assesses overall killing ability by lytic granule secretion (ie, perforin- and granzyme-mediated mechanisms). This testing is available through many commercial laboratories as well as several academic centers [<a href="#rid75">75</a>]. If cytotoxicity testing is abnormal, it should be repeated on three separate occasions, separated in time by at least one month because there are many variables that can compromise the result (eg, damage during shipping of samples, active illness, medications, physiologic stress). External causes of impaired NK function are reviewed below. (See <a class="local">'Differential diagnosis'</a> below.)</p><p>Most cell-based function assays available clinically utilize the K562 erythroleukemia target cell, with the exception of those testing antibody-dependent cellular cytotoxicity, which use the otherwise NK cell-resistant RAJI B cell line opsonized with <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>.</p><p>CD107a upregulation testing is available clinically as a useful surrogate for NK cell cytotoxicity. In this assay, peripheral blood lymphocytes are stimulated with either K562 target cells or a stimulant like PMA and ionomycin and then evaluated for the upregulation of the CD107a protein via flow cytometry. CD107a (also known as LAMP1) is contained inside of NK cell lytic granules and is upregulated on the NK cell surface as the lytic granules are released. Thus, the CD107a assay is a measure of NK cell degranulation, which in most cases is an excellent surrogate of cytotoxicity [<a href="#rid76">76</a>]. However, there are situations in which degranulation (and CD107a upregulation) can be normal but cytotoxicity can be deficient (an example is perforin deficiency, which causes hematophagocytic lymphohistiocytosis), and thus caution is needed so as not to overinterpret.</p><p class="headingAnchor" id="H26523781"><span class="h2">Algorithmic evaluation of NK cell number and function</span><span class="headingEndMark"> — </span>An algorithmic approach to the evaluation of a patient with a suspected NK cell disorder is provided  (<a class="graphic graphic_algorithm graphicRef118303" href="/z/d/graphic/118303.html" rel="external">algorithm 1</a>) and additional conceptual detail is found elsewhere [<a href="#rid77">77</a>]. It is important to consider other causes for depressed NK numbers or function at each step, as true NK cell deficiencies are rare, even among IEIs. (See <a class="local">'Differential diagnosis'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span>The number of NK (CD3-, CD56/16+) cells is determined using flow cytometry  (<a class="graphic graphic_table graphicRef60744" href="/z/d/graphic/60744.html" rel="external">table 2</a>). Standard laboratory panels include CD4- and CD8-positive T cells, B cells, and NK cells. To exclude a transient deficiency, at least two repeat assessments should be performed, ideally when the patient is not experiencing major stress and is free of any infections, drugs, and toxins that can affect NK cells. Note that active herpes virus infections can suppress NK cell numbers but not to the very low levels seen in cNKD. (See <a class="local">'Differential diagnosis'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some hospital and commercial laboratories can provide information about NK subsets (CD56<sup>bright</sup> to CD56<sup>dim</sup> ratio) also. The normal ratio of bright to dim is 1:10. A ratio higher than 1:5 (ie, more than 20 percent bright cells) should be considered abnormal.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>NK cell function is evaluated via cytotoxicity testing, preferentially using a chromium release, or a target cell death-based assay. If cytotoxicity testing is abnormal, it should be repeated on three separate occasions, separated in time by at least one month.</p><p></p><p>Based on the results of these above tests, the following deficiencies can be diagnosed, which may lead to further analysis  (<a class="graphic graphic_algorithm graphicRef118303" href="/z/d/graphic/118303.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>If NK cells were found to be ≤1 percent of lymphocytes and NK cytotoxicity is severely depressed or absent, the patient is diagnosed as having cNKD. Variant analysis of the <em>GATA2</em>, <em>MCM4</em>, <em>RTEL1</em>, <em>IRF8</em>, <em>GINS1, MCM10, </em>and<em> GINS4</em> genes is appropriate in such patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If NK cells were present but NK cytotoxicity was severely depressed or absent, then fNKD is present. Testing for abnormal CD16 should then be performed. (See <a class="local">'Testing for abnormal CD16 as a cause of fNKD'</a> below.)</p><p></p><p class="bulletIndent1">To further assess function, NK cells should be stimulated with interleukin (IL-)2, IL-12, interferon (IFN) alfa (each individually), and then reassayed for cytotoxic activity. This helps determine whether the cytolytic defect is specific to "natural cytotoxicity" or affects activation-induced cytolytic functions. Variant analysis of the <em>FCGR3A</em> gene should also be pursued.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If NK cells were found to be low or absent but NK cytotoxicity is present, then the patient may have a phenotypically abnormal but functional population. This is occasionally seen in some of the NK cell lymphocytoses, which are considered premalignant conditions. (See  <a class="medical medical_review" href="/z/d/html/4538.html" rel="external">"Natural killer (NK) cell large granular lymphocyte leukemia", section on 'Chronic NK cell lymphocytosis'</a>.)</p><p></p><p class="headingAnchor" id="H18238430"><span class="h3">Testing for abnormal CD16 as a cause of fNKD</span><span class="headingEndMark"> — </span>If NK cell numbers are normal but cytotoxicity is depressed, the patient may have an fNKD. In this setting, an evaluation for the presence of abnormal CD16 should be performed. Patients with the L66H alteration have an altered CD16 protein with an abnormal structure that can be detected by certain anti-CD16 antibodies. The clinician should first ascertain which monoclonal antibody reagents were used to identify the NK cells. Most commercial laboratories in the United States use a combination of the 3G8 anti-CD16 antibody and an anti-CD56 antibody. 3G8 will stain the abnormal CD16. If 3G8 was used to detect CD16, the clinician should request that flow cytometry be repeated with two different anti-CD16 antibodies: B73.1 (which will not stain the abnormal CD16) and 3G8 (or others, if available), in separate fluorescent channels  (<a class="graphic graphic_table graphicRef60744" href="/z/d/graphic/60744.html" rel="external">table 2</a>). If the cells stain B73.1 negative and 3G8 positive, the abnormal variant of CD16 is more likely present and gene-sequence confirmation should be obtained. As discussed previously, most patients with an fNKD do not have the abnormal CD16 protein, and pathogenesis in these patients is unknown. (See <a class="local">'Functional NK cell deficiency'</a> above.)</p><p class="headingAnchor" id="H18238436"><span class="h3">Functional assessment following stimulation</span><span class="headingEndMark"> — </span>If the patient's NK cells are present but functionally deficient, they should be stimulated with IL-2, IL-12, IFN alfa (each individually), and then assayed for cytotoxic activity, to determine whether the cytolytic defect is specific to "natural cytotoxicity" or affects activation-induced cytolytic functions  (<a class="graphic graphic_table graphicRef60744" href="/z/d/graphic/60744.html" rel="external">table 2</a>). In the author's program, IL-2 is used as an initial screen given is lower cost and potent effects. In some patients, the abnormal NK cells can mediate cytotoxicity after stimulation with the various cytokines, while other patient's cells are completely unresponsive despite stimulation. Cells that can mediate killing after cytokine stimulation may be unable to activate normally or complete other cytokine-dependent functions. In addition to providing information about the extent of the underlying defect, testing with IL-2 also helps determine if IL-2 therapy would be a potentially useful therapy for that patient. (See  <a class="medical medical_review" href="/z/d/html/3922.html" rel="external">"NK cell deficiency syndromes: Treatment", section on 'Interleukin 2'</a>.)</p><p>Determining the mechanism underlying an NK cell deficiency syndrome requires advanced techniques available in specialized and research laboratories, such as activation-induced CD107a expression [<a href="#rid78">78</a>], granule release, conjugate formation, or others  (<a class="graphic graphic_table graphicRef60744" href="/z/d/graphic/60744.html" rel="external">table 2</a>). These tests can better define deficiencies in cytolytic function and differential responses to cytokines. The CD107a assay has been the topic of substantive investigation [<a href="#rid79">79</a>] and is a useful surrogate for cytotoxicity, although it measures degranulation and not killing. Degranulation and killing can be disconnected, such as in the case of perforin deficiency, where CD107a upregulation is normal after activation, but killing is absent.</p><p>Further investigations, which are mostly performed on a research basis, can include detailed NK cell phenotype to determine the specific presence or absence of NK cell surface receptors that may be critical for regulation of NK cell functions and functions mediated through specific receptors on NK cells  (<a class="graphic graphic_table graphicRef60744" href="/z/d/graphic/60744.html" rel="external">table 2</a>).</p><p class="headingAnchor" id="H18238442"><span class="h3">Variant analysis for known genetic defects</span><span class="headingEndMark"> — </span>If a patient appears to have cNKD, variant analysis of the <em>GATA2</em>, <em>MCM4</em>, <em>RTEL1</em>, <em>IRF8, GINS1, MCM10, </em>and<em> GINS4</em> genes is appropriate. These are contained on many of the commercially available sequencing panels for immunodeficiency and can also be accomplished using whole exome sequencing (WES), which is commercially available as well. Analysis of <em>FCGR3A </em>should be pursued in patients with an fNKD and is best approached by direct single gene sequencing if the flow-cytometry-based screen is positive.</p><p>Panels of tests for various IEIs are commercially available [<a href="#rid80">80,81</a>].</p><p class="headingAnchor" id="H20"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of an NK cell disorder is challenging to make with certainty because there are multiple known diseases and drugs that can suppress NK cell numbers or activities. These include acute stress and significant illness, drugs and toxins, other genetic diseases and IEIs, and autoimmune and malignant diseases. These conditions may impair NK cell development, survival, or specific function.</p><p>The most common alternative explanations for an apparent NK cell deficiency are the following [<a href="#rid82">82</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Incorrect usage or interpretation of laboratory tests. The finding of slightly depressed NK numbers are unlikely to signify a true NK cell deficiency.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Suppression of NK cell function by prescribed medications. (See <a class="local">'Drugs and toxins'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Transient suppression of NK cell function by acute stress or illness [<a href="#rid82">82</a>].</p><p></p><p class="headingAnchor" id="H21"><span class="h2">Drugs and toxins</span><span class="headingEndMark"> — </span>There are a number of medications and toxic exposures that are capable of affecting NK cells [<a href="#rid14">14</a>].</p><p>NK cell numbers can be reduced by the following:</p><p class="bulletIndent1"><span class="glyph">●</span>The anti-CD52 monoclonal antibody <a class="drug drug_general" data-topicid="8725" href="/z/d/drug information/8725.html" rel="external">alemtuzumab</a> (used in B cell chronic lymphocytic leukemia, multiple sclerosis) essentially eliminates NK cells because they express CD52, as do other lymphocytes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Systemic glucocorticoids can reduce NK numbers, although not to undetectable levels [<a href="#rid83">83</a>].</p><p></p><p>NK cell function can be suppressed by several medications. In most instances, cytotoxic activity is inhibited, although the mechanism by which this occurs may be distinct in each case. Examples include:</p><p class="bulletIndent1"><span class="glyph">●</span>Glucocorticoids [<a href="#rid83">83</a>]</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">Ifosfamide</a> and other immunoablative drugs [<a href="#rid84">84</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Alcohol [<a href="#rid85">85</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Salicylates [<a href="#rid86">86</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Medications that increase cyclic adenosine monophosphate (such as <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">theophylline</a>) [<a href="#rid87">87</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Prostaglandins [<a href="#rid88">88</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Cannabinoids [<a href="#rid89">89</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Antimalarials [<a href="#rid90">90</a>]</p><p></p><p class="headingAnchor" id="H22"><span class="h2">Genetic disorders and other immunodeficiencies</span><span class="headingEndMark"> — </span>There are a surprisingly large number of genetic diseases and other IEIs that affect NK cells  (<a class="graphic graphic_table graphicRef64501" href="/z/d/graphic/64501.html" rel="external">table 3</a>) [<a href="#rid15">15,49,91-107</a>]. These disorders may impact NK cell development, survival, or specific function. Most of these disorders have recognizable characteristics or immunologic defects of other cell types.</p><p>Common variable immunodeficiency (CVID) is the most common IEI that can affect NK cell function. Although only a subset of CVID cases have defects in NK cell function, CVID should be entertained in patients with isolated NK cell deficiency because of its relative frequency in the population [<a href="#rid108">108</a>]. CVID is best distinguished from an NK cell deficiency by the demonstration of hypogammaglobulinemia and impaired specific antibody production. (See  <a class="medical medical_review" href="/z/d/html/3928.html" rel="external">"Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults"</a>.)</p><p>In some of these diseases, it is accepted that an NK cell deficiency contributes to the clinical phenotype, such as in familial erythrophagocytic lymphohistiocytosis (a subtype of hemophagocytic lymphohistiocytosis) [<a href="#rid109">109</a>]. In others, such as the radiation hypersensitivity syndromes like Bloom syndrome, the contribution of an NK cell deficiency to the clinical course is unknown.</p><p>NK cell numbers are decreased or absent in disorders affecting NK cell development or survival  (<a class="graphic graphic_table graphicRef64501" href="/z/d/graphic/64501.html" rel="external">table 3</a>). An example is severe combined immunodeficiency (SCID) due to variation of the common gamma chain (<em>IL2RG</em>) [<a href="#rid110">110</a>]. This molecule is required for responsiveness to the cytokines needed for NK cell development, including IL-15. One IL2RG SCID patient was reported to have somatic reversion in his T cells but not NK cells [<a href="#rid111">111</a>]. He had a specific NK cell abnormality and had susceptibility to human papillomavirus (HPV), which was cured following hematopoietic stem cell transplantation and reconstitution of his NK cell defenses. This unusual case of a broader IEI affecting NK cells further illustrates how a specific deficiency of NK cells can present clinically. Other disorders in which NK cell numbers are decreased or absent include certain forms of autosomal recessive SCID (due to variants in <em>JAK3</em> or <em>ADA</em>), Bloom syndrome, and Fanconi anemia. (See  <a class="medical medical_review" href="/z/d/html/3958.html" rel="external">"Mendelian susceptibility to mycobacterial diseases: Specific defects"</a> and  <a class="medical medical_review" href="/z/d/html/3955.html" rel="external">"Severe combined immunodeficiency (SCID): An overview"</a>.)</p><p>In contrast, the diseases in which a gene variant affects NK cell function are characterized by relatively normal populations of NK cells. This category is useful biologically, in that genes can be linked to specific functions in NK cells. An example is familial erythrophagocytic lymphohistiocytosis due to variation of perforin [<a href="#rid109">109</a>]. In this condition, NK cells are unable to kill target cells due to a dysfunctional perforin molecule. (See  <a class="medical medical_review" href="/z/d/html/8384.html" rel="external">"Treatment and prognosis of hemophagocytic lymphohistiocytosis"</a>.)</p><p>The other diseases in which NK cell deficiencies may be seen are Chediak-Higashi syndrome, Griscelli syndrome, X-linked lymphoproliferative syndrome, Wiskott-Aldrich syndrome, IL-12 receptor beta-1 deficiency, and ectodermal dysplasia with immunodeficiency [<a href="#rid15">15,91</a>]. Broadly, the list would include any disease that involves the potential for lymphohistiocytosis (ie, the uncontrolled accumulation of activated T lymphocytes and macrophages in many organs) or results in an increased susceptibility to herpesvirus infection or those with a disproportionate susceptibility to herpesviruses and have a wide array of diverse treatments given the underlying pathophysiology and breadth of immunodeficiency [<a href="#rid112">112</a>]. (See  <a class="medical medical_review" href="/z/d/html/8384.html" rel="external">"Treatment and prognosis of hemophagocytic lymphohistiocytosis"</a> and  <a class="medical medical_review" href="/z/d/html/3913.html" rel="external">"Primary disorders of phagocyte number and/or function: An overview"</a> and  <a class="medical medical_review" href="/z/d/html/3951.html" rel="external">"Syndromic immunodeficiencies"</a> and  <a class="medical medical_review" href="/z/d/html/3935.html" rel="external">"Combined immunodeficiencies: An overview"</a> and  <a class="medical medical_review" href="/z/d/html/3958.html" rel="external">"Mendelian susceptibility to mycobacterial diseases: Specific defects"</a> and  <a class="medical medical_review" href="/z/d/html/3953.html" rel="external">"Wiskott-Aldrich syndrome"</a>.)</p><p class="headingAnchor" id="H4225465888"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112831.html" rel="external">"Society guideline links: Inborn errors of immunity (previously called primary immunodeficiencies)"</a>.)</p><p class="headingAnchor" id="H24"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>NK cell identification and interferon production</strong> – Natural killer (NK) cells are lymphocytes that are part of the innate immune system. They have large cytoplasmic granules  (<a class="graphic graphic_picture graphicRef76027" href="/z/d/graphic/76027.html" rel="external">picture 1</a>) and are CD3-, CD16/56+ upon flow cytometric analysis. NK cells produce interferon-gamma, which activates macrophages and facilitates their respiratory burst. (See <a class="local">'Phenotypic characteristics'</a> above and <a class="local">'Immunostimulation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Normal functions of NK cells</strong> – NK cells constantly survey surrounding cells for abnormalities and kill those cells that fail to display various signatures of health, particularly virally infected and malignant cells. Multiple families of inhibitory receptors on the surface of NK cells, including the killer cell immunoglobulin (Ig)-like receptors, act to restrain the destructive potential of these cells. NK cell cytotoxicity is rapid compared with the responses of other lymphocytes and peaks approximately three days after viral infection. (See <a class="local">'Functions'</a> above and <a class="local">'Mechanisms of killing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features of NK cell disorders</strong> – NK cell disorders are rare and characterized clinically by susceptibility to severe and/or recurrent infection with herpes viruses (especially varicella-zoster virus, herpes simplex viruses I and II, Epstein-Barr virus, and cytomegalovirus) and papilloma viruses  (<a class="graphic graphic_table graphicRef50812" href="/z/d/graphic/50812.html" rel="external">table 1</a>). Many of the patients reported have died in childhood or adolescence, although hematopoietic cell transplantation has been successful in some. (See <a class="local">'Clinical features of NK disorders'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Types of NK cell deficiencies</strong> – NK cell deficiency syndromes are disorders in which either the number, function, or both of NK cells is abnormal, in the absence of any other immunodeficiency, medication, or other condition known to affect NK cells. These syndromes can be divided into two types: classical NK cell deficiency (cNKD) and functional NK cell deficiency (fNKD)  (<a class="graphic graphic_table graphicRef50812" href="/z/d/graphic/50812.html" rel="external">table 1</a>). (See <a class="local">'Classification'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation and diagnosis</strong> – Evaluation for an NK cell deficiency syndrome should be considered in patients with severe, recurrent, or atypical infections with herpesviruses.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Flow cytometry should be performed to quantify NK (CD3-, CD56/16+) cells. If NK cells are low or absent (≤1 percent of peripheral lymphocytes), testing should be repeated at least once when the patient is free of infection or major stress, to exclude a transient deficiency. (See <a class="local">'Evaluation and diagnosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If NK cells are low or absent, then the patient's lymphocytes should be tested for NK cell function (by chromium release assay or flow cytometric cell cytotoxicity assay), which would be expected to be accordingly low or absent, confirming the diagnosis of cNKD  (<a class="graphic graphic_algorithm graphicRef118303" href="/z/d/graphic/118303.html" rel="external">algorithm 1</a>). Functional testing usually requires a specialty laboratory  (<a class="graphic graphic_table graphicRef60744" href="/z/d/graphic/60744.html" rel="external">table 2</a>). If NK cells are present, then cytotoxicity testing should be performed to evaluate their function. Absent or severely decreased function is suggestive of fNKD. (See <a class="local">'Algorithmic evaluation of NK cell number and function'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – A wide and varied differential diagnosis must also be considered because NK cell deficiencies are rare, and medications, infections, and other genetic diseases are more common reasons for altered NK cell number or function. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="headingAnchor" id="H478963138"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges E Richard Stiehm, MD, who contributed as a Section Editor to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Orange JS, Ballas ZK. Natural killer cells in human health and disease. Clin Immunol 2006; 118:1.</a></li><li><a class="nounderline abstract_t">Crinier A, Narni-Mancinelli E, Ugolini S, Vivier E. SnapShot: Natural Killer Cells. Cell 2020; 180:1280.</a></li><li><a class="nounderline abstract_t">Kannan GS, Aquino-Lopez A, Lee DA. Natural killer cells in malignant hematology: A primer for the non-immunologist. Blood Rev 2017; 31:1.</a></li><li><a class="nounderline abstract_t">Björkström NK, Strunz B, Ljunggren HG. Natural killer cells in antiviral immunity. Nat Rev Immunol 2022; 22:112.</a></li><li><a class="nounderline abstract_t">Montaldo E, Vacca P, Vitale C, et al. Human innate lymphoid cells. Immunol Lett 2016; 179:2.</a></li><li><a class="nounderline abstract_t">Lim AI, Verrier T, Vosshenrich CA, Di Santo JP. Developmental options and functional plasticity of innate lymphoid cells. Curr Opin Immunol 2017; 44:61.</a></li><li><a class="nounderline abstract_t">Orange JS. How I Manage Natural Killer Cell Deficiency. J Clin Immunol 2020; 40:13.</a></li><li><a class="nounderline abstract_t">Trinchieri G. Biology of natural killer cells. Adv Immunol 1989; 47:187.</a></li><li><a class="nounderline abstract_t">Angelo LS, Banerjee PP, Monaco-Shawver L, et al. Practical NK cell phenotyping and variability in healthy adults. Immunol Res 2015; 62:341.</a></li><li><a class="nounderline abstract_t">Mace EM, Orange JS. Genetic Causes of Human NK Cell Deficiency and Their Effect on NK Cell Subsets. Front Immunol 2016; 7:545.</a></li><li><a class="nounderline abstract_t">Mahapatra S, Mace EM, Minard CG, et al. High-resolution phenotyping identifies NK cell subsets that distinguish healthy children from adults. PLoS One 2017; 12:e0181134.</a></li><li><a class="nounderline abstract_t">Eiras P, Roldán E, Camarero C, et al. Flow cytometry description of a novel CD3-/CD7+ intraepithelial lymphocyte subset in human duodenal biopsies: potential diagnostic value in coeliac disease. Cytometry 1998; 34:95.</a></li><li><a class="nounderline abstract_t">Moffett A, Loke C. Immunology of placentation in eutherian mammals. Nat Rev Immunol 2006; 6:584.</a></li><li><a class="nounderline abstract_t">Cederbrant K, Marcusson-Ståhl M, Condevaux F, Descotes J. NK-cell activity in immunotoxicity drug evaluation. Toxicology 2003; 185:241.</a></li><li><a class="nounderline abstract_t">Orange JS. Human natural killer cell deficiencies. Curr Opin Allergy Clin Immunol 2006; 6:399.</a></li><li><a class="nounderline abstract_t">Freud AG, Mundy-Bosse BL, Yu J, Caligiuri MA. The Broad Spectrum of Human Natural Killer Cell Diversity. Immunity 2017; 47:820.</a></li><li><a class="nounderline abstract_t">Strowig T, Brilot F, Münz C. Noncytotoxic functions of NK cells: direct pathogen restriction and assistance to adaptive immunity. J Immunol 2008; 180:7785.</a></li><li><a class="nounderline abstract_t">Hanna J, Bechtel P, Zhai Y, et al. Novel insights on human NK cells' immunological modalities revealed by gene expression profiling. J Immunol 2004; 173:6547.</a></li><li><a class="nounderline abstract_t">Biassoni R, Cantoni C, Pende D, et al. Human natural killer cell receptors and co-receptors. Immunol Rev 2001; 181:203.</a></li><li><a class="nounderline abstract_t">Taniguchi M, Harada M, Kojo S, et al. The regulatory role of Valpha14 NKT cells in innate and acquired immune response. Annu Rev Immunol 2003; 21:483.</a></li><li><a class="nounderline abstract_t">Ljunggren HG, Kärre K. In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today 1990; 11:237.</a></li><li><a class="nounderline abstract_t">Orange JS, Fassett MS, Koopman LA, et al. Viral evasion of natural killer cells. Nat Immunol 2002; 3:1006.</a></li><li><a class="nounderline abstract_t">Lanier LL. Evolutionary struggles between NK cells and viruses. Nat Rev Immunol 2008; 8:259.</a></li><li><a class="nounderline abstract_t">Stebbins CC, Watzl C, Billadeau DD, et al. Vav1 dephosphorylation by the tyrosine phosphatase SHP-1 as a mechanism for inhibition of cellular cytotoxicity. Mol Cell Biol 2003; 23:6291.</a></li><li><a class="nounderline abstract_t">Moretta A, Bottino C, Vitale M, et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 2001; 19:197.</a></li><li><a class="nounderline abstract_t">Kumar V, McNerney ME. A new self: MHC-class-I-independent natural-killer-cell self-tolerance. Nat Rev Immunol 2005; 5:363.</a></li><li><a class="nounderline abstract_t">Mandelboim O, Lieberman N, Lev M, et al. Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature 2001; 409:1055.</a></li><li><a class="nounderline abstract_t">Gwalani LA, Orange JS. Single Degranulations in NK Cells Can Mediate Target Cell Killing. J Immunol 2018; 200:3231.</a></li><li><a class="nounderline abstract_t">Prager I, Liesche C, van Ooijen H, et al. NK cells switch from granzyme B to death receptor-mediated cytotoxicity during serial killing. J Exp Med 2019; 216:2113.</a></li><li><a class="nounderline abstract_t">Orange JS. Formation and function of the lytic NK-cell immunological synapse. Nat Rev Immunol 2008; 8:713.</a></li><li><a class="nounderline abstract_t">Dagher R, Kumar V, Copenhaver AM, et al. Novel mechanisms of action contributing to benralizumab's potent anti-eosinophilic activity. Eur Respir J 2022; 59.</a></li><li><a class="nounderline abstract_t">Poznanski SM, Portillo A, Mukherjee M, et al. Benralizumab's anti-eosinophil efficacy may be decreased by impaired NK cell activity. Eur Respir J 2022; 59.</a></li><li><a class="nounderline abstract_t">Levy O, Orange JS, Hibberd P, et al. Disseminated varicella infection due to the vaccine strain of varicella-zoster virus, in a patient with a novel deficiency in natural killer T cells. J Infect Dis 2003; 188:948.</a></li><li><a class="nounderline abstract_t">Lee SJ, Cho YN, Kim TJ, et al. Natural killer T cell deficiency in active adult-onset Still's Disease: correlation of deficiency of natural killer T cells with dysfunction of natural killer cells. Arthritis Rheum 2012; 64:2868.</a></li><li><a class="nounderline abstract_t">Spinner MA, Sanchez LA, Hsu AP, et al. GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity. Blood 2014; 123:809.</a></li><li><a class="nounderline abstract_t">Wang D, Uyemura B, Hashemi E, et al. Role of GATA2 in Human NK Cell Development. Crit Rev Immunol 2021; 41:21.</a></li><li><a class="nounderline abstract_t">Mace EM, Bigley V, Gunesch JT, et al. Biallelic mutations in IRF8 impair human NK cell maturation and function. J Clin Invest 2017; 127:306.</a></li><li><a class="nounderline abstract_t">Tangye SG, Al-Herz W, Bousfiha A, et al. Human Inborn Errors of Immunity: 2022 Update on the Classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol 2022; 42:1473.</a></li><li><a class="nounderline abstract_t">Orange JS. Natural killer cell deficiency. J Allergy Clin Immunol 2013; 132:515.</a></li><li><a class="nounderline abstract_t">Biron CA, Byron KS, Sullivan JL. Severe herpesvirus infections in an adolescent without natural killer cells. N Engl J Med 1989; 320:1731.</a></li><li><a class="nounderline abstract_t">Mace EM, Hsu AP, Monaco-Shawver L, et al. Mutations in GATA2 cause human NK cell deficiency with specific loss of the CD56(bright) subset. Blood 2013; 121:2669.</a></li><li><a class="nounderline abstract_t">Vinh DC, Patel SY, Uzel G, et al. Autosomal dominant and sporadic monocytopenia with susceptibility to mycobacteria, fungi, papillomaviruses, and myelodysplasia. Blood 2010; 115:1519.</a></li><li><a class="nounderline abstract_t">Hsu AP, Sampaio EP, Khan J, et al. Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome. Blood 2011; 118:2653.</a></li><li><a class="nounderline abstract_t">Dickinson RE, Griffin H, Bigley V, et al. Exome sequencing identifies GATA-2 mutation as the cause of dendritic cell, monocyte, B and NK lymphoid deficiency. Blood 2011; 118:2656.</a></li><li><a class="nounderline abstract_t">Ostergaard P, Simpson MA, Connell FC, et al. Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome). Nat Genet 2011; 43:929.</a></li><li><a class="nounderline abstract_t">Hahn CN, Chong CE, Carmichael CL, et al. Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia. Nat Genet 2011; 43:1012.</a></li><li><a class="nounderline abstract_t">Wieser R, Volz A, Vinatzer U, et al. Transcription factor GATA-2 gene is located near 3q21 breakpoints in myeloid leukemia. Biochem Biophys Res Commun 2000; 273:239.</a></li><li><a class="nounderline abstract_t">Wlodarski MW, Hirabayashi S, Pastor V, et al. Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescents. Blood 2016; 127:1387.</a></li><li><a class="nounderline abstract_t">Orange JS. Unraveling human natural killer cell deficiency. J Clin Invest 2012; 122:798.</a></li><li><a class="nounderline abstract_t">Eidenschenk C, Dunne J, Jouanguy E, et al. A novel primary immunodeficiency with specific natural-killer cell deficiency maps to the centromeric region of chromosome 8. Am J Hum Genet 2006; 78:721.</a></li><li><a class="nounderline abstract_t">Hughes CR, Guasti L, Meimaridou E, et al. MCM4 mutation causes adrenal failure, short stature, and natural killer cell deficiency in humans. J Clin Invest 2012; 122:814.</a></li><li><a class="nounderline abstract_t">Gineau L, Cognet C, Kara N, et al. Partial MCM4 deficiency in patients with growth retardation, adrenal insufficiency, and natural killer cell deficiency. J Clin Invest 2012; 122:821.</a></li><li><a class="nounderline abstract_t">Etzioni A, Eidenschenk C, Katz R, et al. Fatal varicella associated with selective natural killer cell deficiency. J Pediatr 2005; 146:423.</a></li><li><a class="nounderline abstract_t">Hanna S, Béziat V, Jouanguy E, et al. A homozygous mutation of RTEL1 in a child presenting with an apparently isolated natural killer cell deficiency. J Allergy Clin Immunol 2015; 136:1113.</a></li><li><a class="nounderline abstract_t">Fedick AM, Shi L, Jalas C, et al. Carrier screening of RTEL1 mutations in the Ashkenazi Jewish population. Clin Genet 2015; 88:177.</a></li><li><a class="nounderline abstract_t">Fleisher G, Starr S, Koven N, et al. A non-x-linked syndrome with susceptibility to severe Epstein-Barr virus infections. J Pediatr 1982; 100:727.</a></li><li><a class="nounderline abstract_t">Hambleton S, Salem S, Bustamante J, et al. IRF8 mutations and human dendritic-cell immunodeficiency. N Engl J Med 2011; 365:127.</a></li><li><a class="nounderline abstract_t">Cottineau J, Kottemann MC, Lach FP, et al. Inherited GINS1 deficiency underlies growth retardation along with neutropenia and NK cell deficiency. J Clin Invest 2017; 127:1991.</a></li><li><a class="nounderline abstract_t">Bernard F, Picard C, Cormier-Daire V, et al. A novel developmental and immunodeficiency syndrome associated with intrauterine growth retardation and a lack of natural killer cells. Pediatrics 2004; 113:136.</a></li><li><a class="nounderline abstract_t">Eidenschenk C, Jouanguy E, Alcaïs A, et al. Familial NK cell deficiency associated with impaired IL-2- and IL-15-dependent survival of lymphocytes. J Immunol 2006; 177:8835.</a></li><li><a class="nounderline abstract_t">Mace EM, Paust S, Conte MI, et al. Human NK cell deficiency as a result of biallelic mutations in MCM10. J Clin Invest 2020; 130:5272.</a></li><li><a class="nounderline abstract_t">Baxley RM, Leung W, Schmit MM, et al. Bi-allelic MCM10 variants associated with immune dysfunction and cardiomyopathy cause telomere shortening. Nat Commun 2021; 12:1626.</a></li><li><a class="nounderline abstract_t">Wendland T, Herren S, Yawalkar N, et al. Strong alpha beta and gamma delta TCR response in a patient with disseminated Mycobacterium avium infection and lack of NK cells and monocytopenia. Immunol Lett 2000; 72:75.</a></li><li><a class="nounderline abstract_t">Akiba H, Motoki Y, Satoh M, et al. Recalcitrant trichophytic granuloma associated with NK-cell deficiency in a SLE patient treated with corticosteroid. Eur J Dermatol 2001; 11:58.</a></li><li><a class="nounderline abstract_t">Ballas ZK, Turner JM, Turner DA, et al. A patient with simultaneous absence of "classical" natural killer cells (CD3-, CD16+, and NKH1+) and expansion of CD3+, CD4-, CD8-, NKH1+ subset. J Allergy Clin Immunol 1990; 85:453.</a></li><li><a class="nounderline abstract_t">Shaw RK, Issekutz AC, Fraser R, et al. Bilateral adrenal EBV-associated smooth muscle tumors in a child with a natural killer cell deficiency. Blood 2012; 119:4009.</a></li><li><a class="nounderline abstract_t">Grier JT, Forbes LR, Monaco-Shawver L, et al. Human immunodeficiency-causing mutation defines CD16 in spontaneous NK cell cytotoxicity. J Clin Invest 2012; 122:3769.</a></li><li><a class="nounderline abstract_t">Jawahar S, Moody C, Chan M, et al. Natural Killer (NK) cell deficiency associated with an epitope-deficient Fc receptor type IIIA (CD16-II). Clin Exp Immunol 1996; 103:408.</a></li><li><a class="nounderline abstract_t">de Vries E, Koene HR, Vossen JM, et al. Identification of an unusual Fc gamma receptor IIIa (CD16) on natural killer cells in a patient with recurrent infections. Blood 1996; 88:3022.</a></li><li><a class="nounderline abstract_t">de Haas M, Koene HR, Kleijer M, et al. A triallelic Fc gamma receptor type IIIA polymorphism influences the binding of human IgG by NK cell Fc gamma RIIIa. J Immunol 1996; 156:2948.</a></li><li><a class="nounderline abstract_t">Aoukaty A, Lee IF, Wu J, Tan R. Chronic active Epstein-Barr virus infection associated with low expression of leukocyte-associated immunoglobulin-like receptor-1 (LAIR-1) on natural killer cells. J Clin Immunol 2003; 23:141.</a></li><li><a class="nounderline abstract_t">Lopez C, Kirkpatrick D, Read SE, et al. Correlation between low natural killing of fibroblasts infected with herpes simplex virus type 1 and susceptibility to herpesvirus infections. J Infect Dis 1983; 147:1030.</a></li><li><a class="nounderline abstract_t">Komiyama A, Kawai H, Yabuhara A, et al. Natural killer cell immunodeficiency in siblings: defective killing in the absence of natural killer cytotoxic factor activity in natural killer and lymphokine-activated killer cytotoxicities. Pediatrics 1990; 85:323.</a></li><li class="breakAll">Texas Children's Hospital, Houston, Texas (Drs. Lisa Forbes and Nicholas Rider); Cincinnati Children's Hospital Medical Center, Cincinatti, Ohio (Drs. Kim Risma and Rebecca Marsh); University of Iowa, Iowa City, Iowa (Dr. Zuhair Ballas); Columbia University Medical Center, New York, NY (Dr. Jordan Orange); Universita degli studi di Brescia, Italy (Dr. Raffaele Badolato); Paris Necker Hospital (Dr. Capucine Picard), Paris, France.</li><li class="breakAll">Academic centers include the University of Iowa, Cincinnati Children's Hospital, and Children's Hospital of Philadelphia.</li><li><a class="nounderline abstract_t">Rubin TS, Zhang K, Gifford C, et al. Perforin and CD107a testing is superior to NK cell function testing for screening patients for genetic HLH. Blood 2017; 129:2993.</a></li><li><a class="nounderline abstract_t">Lam MT, Mace EM, Orange JS. A research-driven approach to the identification of novel natural killer cell deficiencies affecting cytotoxic function. Blood 2020; 135:629.</a></li><li class="breakAll">One commercial laboratory that performs this test is the Cincinnati Children's Hospital Diagnostic Immunology Laboratory. Search on "CD107a" in the test menu. http://www.cincinnatichildrens.org/service/c/cancer-blood/hcp/diagnostic-lab/default/ (Accessed on June 18, 2013).</li><li><a class="nounderline abstract_t">Bryceson YT, Pende D, Maul-Pavicic A, et al. A prospective evaluation of degranulation assays in the rapid diagnosis of familial hemophagocytic syndromes. Blood 2012; 119:2754.</a></li><li><a class="nounderline abstract_t">Heimall JR, Hagin D, Hajjar J, et al. Use of Genetic Testing for Primary Immunodeficiency Patients. J Clin Immunol 2018; 38:320.</a></li><li><a class="nounderline abstract_t">Chinn IK, Chan AY, Chen K, et al. Diagnostic interpretation of genetic studies in patients with primary immunodeficiency diseases: A working group report of the Primary Immunodeficiency Diseases Committee of the American Academy of Allergy, Asthma &amp; Immunology. J Allergy Clin Immunol 2020; 145:46.</a></li><li><a class="nounderline abstract_t">Zorrilla EP, Luborsky L, McKay JR, et al. The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain Behav Immun 2001; 15:199.</a></li><li><a class="nounderline abstract_t">Nair MP, Schwartz SA. Immunomodulatory effects of corticosteroids on natural killer and antibody-dependent cellular cytotoxic activities of human lymphocytes. J Immunol 1984; 132:2876.</a></li><li><a class="nounderline abstract_t">Botzler C, Kis K, Issels R, Multhoff G. A comparison of the effects of ifosfamide vs. mafosfamide treatment on intracellular glutathione levels and immunological functions of immunocompetent lymphocyte subsets. Exp Hematol 1997; 25:338.</a></li><li><a class="nounderline abstract_t">Nair MP, Kronfol ZA, Schwartz SA. Effects of alcohol and nicotine on cytotoxic functions of human lymphocytes. Clin Immunol Immunopathol 1990; 54:395.</a></li><li><a class="nounderline abstract_t">Knight SC, Harding B, Burman S, Mertin J. Cell number requirements for lymphocyte stimulation in vitro: changes during the course of multiple sclerosis and the effects of immunosuppression. Clin Exp Immunol 1981; 46:61.</a></li><li><a class="nounderline abstract_t">Roder JC, Klein M. Target-effector interaction in the natural killer cell system. IV. Modulation by cyclic nucleotides. J Immunol 1979; 123:2785.</a></li><li><a class="nounderline abstract_t">Hall TJ, Chen SH, Brostoff J, Lydyard PM. Modulation of human natural killer cell activity by pharmacological mediators. Clin Exp Immunol 1983; 54:493.</a></li><li><a class="nounderline abstract_t">Specter S, Rivenbark M, Newton C, et al. Prevention and reversal of delta-9-tetrahydrocannabinol induced depression of natural killer cell activity by interleukin-2. Int J Immunopharmacol 1989; 11:63.</a></li><li><a class="nounderline abstract_t">Ausiello CM, Barbieri P, Spagnoli GC, et al. In vivo effects of chloroquine treatment on spontaneous and interferon-induced natural killer activities in rheumatoid arthritis patients. Clin Exp Rheumatol 1986; 4:255.</a></li><li><a class="nounderline abstract_t">Orange JS. Human natural killer cell deficiencies and susceptibility to infection. Microbes Infect 2002; 4:1545.</a></li><li><a class="nounderline abstract_t">Wood SM, Ljunggren HG, Bryceson YT. Insights into NK cell biology from human genetics and disease associations. Cell Mol Life Sci 2011; 68:3479.</a></li><li><a class="nounderline abstract_t">Ham H, Billadeau DD. Human immunodeficiency syndromes affecting human natural killer cell cytolytic activity. Front Immunol 2014; 5:2.</a></li><li><a class="nounderline abstract_t">Vargas-Hernández A, Forbes LR. The Impact of Immunodeficiency on NK Cell Maturation and Function. Curr Allergy Asthma Rep 2019; 19:2.</a></li><li><a class="nounderline abstract_t">Lam MT, Coppola S, Krumbach OHF, et al. A novel disorder involving dyshematopoiesis, inflammation, and HLH due to aberrant CDC42 function. J Exp Med 2019; 216:2778.</a></li><li><a class="nounderline abstract_t">Cook SA, Comrie WA, Poli MC, et al. HEM1 deficiency disrupts mTORC2 and F-actin control in inherited immunodysregulatory disease. Science 2020; 369:202.</a></li><li><a class="nounderline abstract_t">Aird A, Lagos M, Vargas-Hernández A, et al. Novel Heterozygous Mutation in NFKB2 Is Associated With Early Onset CVID and a Functional Defect in NK Cells Complicated by Disseminated CMV Infection and Severe Nephrotic Syndrome. Front Pediatr 2019; 7:303.</a></li><li><a class="nounderline abstract_t">Ruiz-García R, Vargas-Hernández A, Chinn IK, et al. Mutations in PI3K110δ cause impaired natural killer cell function partially rescued by rapamycin treatment. J Allergy Clin Immunol 2018; 142:605.</a></li><li><a class="nounderline abstract_t">Vargas-Hernández A, Mace EM, Zimmerman O, et al. Ruxolitinib partially reverses functional natural killer cell deficiency in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations. J Allergy Clin Immunol 2018; 141:2142.</a></li><li><a class="nounderline abstract_t">Vargas-Hernández A, Witalisz-Siepracka A, Prchal-Murphy M, et al. Human signal transducer and activator of transcription 5b (STAT5b) mutation causes dysregulated human natural killer cell maturation and impaired lytic function. J Allergy Clin Immunol 2020; 145:345.</a></li><li><a class="nounderline abstract_t">Burk CM, Coffey KE, Mace EM, et al. Immunodeficiency, centromeric instability, and facial anomalies (ICF) syndrome with NK dysfunction and EBV-driven malignancy treated with stem cell transplantation. J Allergy Clin Immunol Pract 2020; 8:1103.</a></li><li><a class="nounderline abstract_t">Salzer E, Cagdas D, Hons M, et al. RASGRP1 deficiency causes immunodeficiency with impaired cytoskeletal dynamics. Nat Immunol 2016; 17:1352.</a></li><li><a class="nounderline abstract_t">Mace EM, Orange JS. Lytic immune synapse function requires filamentous actin deconstruction by Coronin 1A. Proc Natl Acad Sci U S A 2014; 111:6708.</a></li><li><a class="nounderline abstract_t">Chaigne-Delalande B, Li FY, O'Connor GM, et al. Mg2+ regulates cytotoxic functions of NK and CD8 T cells in chronic EBV infection through NKG2D. Science 2013; 341:186.</a></li><li><a class="nounderline abstract_t">Serwas NK, Hoeger B, Ardy RC, et al. Human DEF6 deficiency underlies an immunodeficiency syndrome with systemic autoimmunity and aberrant CTLA-4 homeostasis. Nat Commun 2019; 10:3106.</a></li><li><a class="nounderline abstract_t">Willmann KL, Klaver S, Doğu F, et al. Biallelic loss-of-function mutation in NIK causes a primary immunodeficiency with multifaceted aberrant lymphoid immunity. Nat Commun 2014; 5:5360.</a></li><li><a class="nounderline abstract_t">Volpi S, Cicalese MP, Tuijnenburg P, et al. A combined immunodeficiency with severe infections, inflammation, and allergy caused by ARPC1B deficiency. J Allergy Clin Immunol 2019; 143:2296.</a></li><li><a class="nounderline abstract_t">Koren HS, Amos DB, Buckley RH. Natural killing in immunodeficient patients. J Immunol 1978; 120:796.</a></li><li><a class="nounderline abstract_t">Stepp SE, Dufourcq-Lagelouse R, Le Deist F, et al. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science 1999; 286:1957.</a></li><li><a class="nounderline abstract_t">Buckley RH, Schiff RI, Schiff SE, et al. Human severe combined immunodeficiency: genetic, phenotypic, and functional diversity in one hundred eight infants. J Pediatr 1997; 130:378.</a></li><li><a class="nounderline abstract_t">Lisco A, Hsu AP, Dimitrova D, et al. Treatment of Relapsing HPV Diseases by Restored Function of Natural Killer Cells. N Engl J Med 2021; 385:921.</a></li><li><a class="nounderline abstract_t">Eguizabal C, Herrera L, Inglés-Ferrándiz M, Izpisua Belmonte JC. Treating primary immunodeficiencies with defects in NK cells: from stem cell therapy to gene editing. Stem Cell Res Ther 2020; 11:453.</a></li></ol></div><div id="topicVersionRevision">Topic 3949 Version 20.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16337194" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Natural killer cells in human health and disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32200803" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : SnapShot: Natural Killer Cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27665023" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Natural killer cells in malignant hematology: A primer for the non-immunologist.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34117484" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Natural killer cells in antiviral immunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26844414" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Human innate lymphoid cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28359987" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Developmental options and functional plasticity of innate lymphoid cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31754930" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : How I Manage Natural Killer Cell Deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2683611" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Biology of natural killer cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26013798" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Practical NK cell phenotyping and variability in healthy adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27994588" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Genetic Causes of Human NK Cell Deficiency and Their Effect on NK Cell Subsets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28767726" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : High-resolution phenotyping identifies NK cell subsets that distinguish healthy children from adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9579607" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Flow cytometry description of a novel CD3-/CD7+ intraepithelial lymphocyte subset in human duodenal biopsies: potential diagnostic value in coeliac disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16868549" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Immunology of placentation in eutherian mammals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12581699" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : NK-cell activity in immunotoxicity drug evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17088643" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Human natural killer cell deficiencies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29166586" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The Broad Spectrum of Human Natural Killer Cell Diversity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18523242" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Noncytotoxic functions of NK cells: direct pathogen restriction and assistance to adaptive immunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15557145" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Novel insights on human NK cells' immunological modalities revealed by gene expression profiling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11513142" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Human natural killer cell receptors and co-receptors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12543936" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The regulatory role of Valpha14 NKT cells in innate and acquired immune response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2201309" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : In search of the 'missing self': MHC molecules and NK cell recognition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12407408" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Viral evasion of natural killer cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18340344" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Evolutionary struggles between NK cells and viruses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12917349" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Vav1 dephosphorylation by the tyrosine phosphatase SHP-1 as a mechanism for inhibition of cellular cytotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11244035" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15841099" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : A new self: MHC-class-I-independent natural-killer-cell self-tolerance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11234016" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29592963" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Single Degranulations in NK Cells Can Mediate Target Cell Killing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31270246" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : NK cells switch from granzyme B to death receptor-mediated cytotoxicity during serial killing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19172692" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Formation and function of the lytic NK-cell immunological synapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34289975" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Novel mechanisms of action contributing to benralizumab's potent anti-eosinophilic activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34887323" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Benralizumab's anti-eosinophil efficacy may be decreased by impaired NK cell activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14513412" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Disseminated varicella infection due to the vaccine strain of varicella-zoster virus, in a patient with a novel deficiency in natural killer T cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22605480" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Natural killer T cell deficiency in active adult-onset Still's Disease: correlation of deficiency of natural killer T cells with dysfunction of natural killer cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24227816" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34348000" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Role of GATA2 in Human NK Cell Development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27893462" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Biallelic mutations in IRF8 impair human NK cell maturation and function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35748970" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Human Inborn Errors of Immunity: 2022 Update on the Classification from the International Union of Immunological Societies Expert Committee.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23993353" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Natural killer cell deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2543925" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Severe herpesvirus infections in an adolescent without natural killer cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23365458" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Mutations in GATA2 cause human NK cell deficiency with specific loss of the CD56(bright) subset.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20040766" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Autosomal dominant and sporadic monocytopenia with susceptibility to mycobacteria, fungi, papillomaviruses, and myelodysplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21670465" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21765025" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Exome sequencing identifies GATA-2 mutation as the cause of dendritic cell, monocyte, B and NK lymphoid deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21892158" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21892162" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10873593" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Transcription factor GATA-2 gene is located near 3q21 breakpoints in myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26702063" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22354165" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Unraveling human natural killer cell deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16532402" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : A novel primary immunodeficiency with specific natural-killer cell deficiency maps to the centromeric region of chromosome 8.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22354170" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : MCM4 mutation causes adrenal failure, short stature, and natural killer cell deficiency in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22354167" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Partial MCM4 deficiency in patients with growth retardation, adrenal insufficiency, and natural killer cell deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15756234" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Fatal varicella associated with selective natural killer cell deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26025130" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : A homozygous mutation of RTEL1 in a child presenting with an apparently isolated natural killer cell deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25047097" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Carrier screening of RTEL1 mutations in the Ashkenazi Jewish population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6279813" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : A non-x-linked syndrome with susceptibility to severe Epstein-Barr virus infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21524210" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : IRF8 mutations and human dendritic-cell immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28414293" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Inherited GINS1 deficiency underlies growth retardation along with neutropenia and NK cell deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14702466" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : A novel developmental and immunodeficiency syndrome associated with intrauterine growth retardation and a lack of natural killer cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17142786" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Familial NK cell deficiency associated with impaired IL-2- and IL-15-dependent survival of lymphocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32865517" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Human NK cell deficiency as a result of biallelic mutations in MCM10.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33712616" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Bi-allelic MCM10 variants associated with immune dysfunction and cardiomyopathy cause telomere shortening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10841941" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Strong alpha beta and gamma delta TCR response in a patient with disseminated Mycobacterium avium infection and lack of NK cells and monocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11174142" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Recalcitrant trichophytic granuloma associated with NK-cell deficiency in a SLE patient treated with corticosteroid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2303649" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : A patient with simultaneous absence of "classical" natural killer cells (CD3-, CD16+, and NKH1+) and expansion of CD3+, CD4-, CD8-, NKH1+ subset.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22427204" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Bilateral adrenal EBV-associated smooth muscle tumors in a child with a natural killer cell deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23006327" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Human immunodeficiency-causing mutation defines CD16 in spontaneous NK cell cytotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8608639" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Natural Killer (NK) cell deficiency associated with an epitope-deficient Fc receptor type IIIA (CD16-II).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8874200" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Identification of an unusual Fc gamma receptor IIIa (CD16) on natural killer cells in a patient with recurrent infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8609432" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : A triallelic Fc gamma receptor type IIIA polymorphism influences the binding of human IgG by NK cell Fc gamma RIIIa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12757266" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Chronic active Epstein-Barr virus infection associated with low expression of leukocyte-associated immunoglobulin-like receptor-1 (LAIR-1) on natural killer cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6304202" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Correlation between low natural killing of fibroblasts infected with herpes simplex virus type 1 and susceptibility to herpesvirus infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2304785" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Natural killer cell immunodeficiency in siblings: defective killing in the absence of natural killer cytotoxic factor activity in natural killer and lymphokine-activated killer cytotoxicities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2304785" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Natural killer cell immunodeficiency in siblings: defective killing in the absence of natural killer cytotoxic factor activity in natural killer and lymphokine-activated killer cytotoxicities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2304785" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Natural killer cell immunodeficiency in siblings: defective killing in the absence of natural killer cytotoxic factor activity in natural killer and lymphokine-activated killer cytotoxicities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28270454" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Perforin and CD107a testing is superior to NK cell function testing for screening patients for genetic HLH.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31945148" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : A research-driven approach to the identification of novel natural killer cell deficiencies affecting cytotoxic function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31945148" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : A research-driven approach to the identification of novel natural killer cell deficiencies affecting cytotoxic function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22294731" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : A prospective evaluation of degranulation assays in the rapid diagnosis of familial hemophagocytic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29675737" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Use of Genetic Testing for Primary Immunodeficiency Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31568798" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Diagnostic interpretation of genetic studies in patients with primary immunodeficiency diseases: A working group report of the Primary Immunodeficiency Diseases Committee of the American Academy of Allergy, Asthma&amp;Immunology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11566046" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : The relationship of depression and stressors to immunological assays: a meta-analytic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6202765" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Immunomodulatory effects of corticosteroids on natural killer and antibody-dependent cellular cytotoxic activities of human lymphocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9131009" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : A comparison of the effects of ifosfamide vs. mafosfamide treatment on intracellular glutathione levels and immunological functions of immunocompetent lymphocyte subsets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1689229" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Effects of alcohol and nicotine on cytotoxic functions of human lymphocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7039882" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Cell number requirements for lymphocyte stimulation in vitro: changes during the course of multiple sclerosis and the effects of immunosuppression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/227959" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Target-effector interaction in the natural killer cell system. IV. Modulation by cyclic nucleotides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6317242" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Modulation of human natural killer cell activity by pharmacological mediators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2540100" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Prevention and reversal of delta-9-tetrahydrocannabinol induced depression of natural killer cell activity by interleukin-2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3769242" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : In vivo effects of chloroquine treatment on spontaneous and interferon-induced natural killer activities in rheumatoid arthritis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12505527" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Human natural killer cell deficiencies and susceptibility to infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21874350" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Insights into NK cell biology from human genetics and disease associations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24478771" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Human immunodeficiency syndromes affecting human natural killer cell cytolytic activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30661124" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : The Impact of Immunodeficiency on NK Cell Maturation and Function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31601675" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : A novel disorder involving dyshematopoiesis, inflammation, and HLH due to aberrant CDC42 function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32647003" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : HEM1 deficiency disrupts mTORC2 and F-actin control in inherited immunodysregulatory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31417880" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Novel Heterozygous Mutation in NFKB2 Is Associated With Early Onset CVID and a Functional Defect in NK Cells Complicated by Disseminated CMV Infection and Severe Nephrotic Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29330011" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Mutations in PI3K110δcause impaired natural killer cell function partially rescued by rapamycin treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29111217" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Ruxolitinib partially reverses functional natural killer cell deficiency in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31600547" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Human signal transducer and activator of transcription 5b (STAT5b) mutation causes dysregulated human natural killer cell maturation and impaired lytic function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31520839" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Immunodeficiency, centromeric instability, and facial anomalies (ICF) syndrome with NK dysfunction and EBV-driven malignancy treated with stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27776107" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : RASGRP1 deficiency causes immunodeficiency with impaired cytoskeletal dynamics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24760828" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Lytic immune synapse function requires filamentous actin deconstruction by Coronin 1A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23846901" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Mg2+ regulates cytotoxic functions of NK and CD8 T cells in chronic EBV infection through NKG2D.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31308374" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Human DEF6 deficiency underlies an immunodeficiency syndrome with systemic autoimmunity and aberrant CTLA-4 homeostasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25406581" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Biallelic loss-of-function mutation in NIK causes a primary immunodeficiency with multifaceted aberrant lymphoid immunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30771411" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : A combined immunodeficiency with severe infections, inflammation, and allergy caused by ARPC1B deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/632589" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Natural killing in immunodeficient patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10583959" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Perforin gene defects in familial hemophagocytic lymphohistiocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9063412" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Human severe combined immunodeficiency: genetic, phenotypic, and functional diversity in one hundred eight infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34469647" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Treatment of Relapsing HPV Diseases by Restored Function of Natural Killer Cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33109263" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Treating primary immunodeficiencies with defects in NK cells: from stem cell therapy to gene editing.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
